Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTLS-181
- Development stage
- Preclinical
- Lead developer
- Primetime
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PTLS-181 is an investigational small-molecule drug being developed by Primetime Life Sciences as a novel treatment for depressive disorders, with development supported by a U.S. NIH Fast-Track Phase II SBIR grant focused on depression. Publicly available information indicates it is a central nervous system–active agent in the nervous system diseases therapeutic area, but its precise molecular target, detailed mechanism of action, and chemical class have not yet been disclosed. Early-stage development is aimed at addressing unmet need in depression, potentially via a differentiated mechanism relative to existing antidepressants, though specific pharmacology remains proprietary.
Beyond the preview
Go deeper on PTLS-181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTLS-181.